How gut bacteria affects lung cancer treatment response

Researchers are studying the bacteria in your gut to understand how they might affect how your body responds to lung cancer treatment. This pilot study will compare gut bacteria in patients receiving different types of approved cancer medications—such as pembrolizumab, nivolumab, atezolizumab, durvalumab, or tyrosine kinase inhibitors—either alone or combined with chemotherapy. By learning more about these connections, the research team hopes to better predict who will benefit most from treatment and who may experience more side effects.

Recent scientific discoveries suggest that the trillions of bacteria living in your digestive system may play a role in how well immunotherapy and other cancer treatments work. This study aims to explore that connection, which could eventually help doctors personalize treatment choices and manage side effects better for lung cancer patients.